S&P 500   4,109.31 (+1.44%)
DOW   33,274.15 (+1.26%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
S&P 500   4,109.31 (+1.44%)
DOW   33,274.15 (+1.26%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
S&P 500   4,109.31 (+1.44%)
DOW   33,274.15 (+1.26%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
S&P 500   4,109.31 (+1.44%)
DOW   33,274.15 (+1.26%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
NASDAQ:VRCA

Verrica Pharmaceuticals - VRCA Stock Forecast, Price & News

$6.50
-0.14 (-2.11%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$6.37
$6.73
50-Day Range
$4.15
$8.51
52-Week Range
$1.77
$9.22
Volume
156,837 shs
Average Volume
185,587 shs
Market Capitalization
$272.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.67

Verrica Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
64.1% Upside
$10.67 Price Target
Short Interest
Healthy
1.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
1.03mentions of Verrica Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.95) to ($0.96) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

356th out of 1,004 stocks

Pharmaceutical Preparations Industry

161st out of 489 stocks


VRCA stock logo

About Verrica Pharmaceuticals (NASDAQ:VRCA) Stock

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Receive VRCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRCA Stock News Headlines

Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
NOVN: NDA Submitted
Verrica Flat on Forwarding NDA to FDA
Verrica Pharmaceuticals Inc
See More Headlines
Receive VRCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRCA Company Calendar

Last Earnings
3/06/2023
Today
3/31/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VRCA
Fax
N/A
Employees
38
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.67
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+64.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-24,490,000.00
Net Margins
-271.11%
Pretax Margin
-271.11%

Debt

Sales & Book Value

Annual Sales
$9.03 million
Book Value
$0.97 per share

Miscellaneous

Free Float
23,646,000
Market Cap
$272.03 million
Optionable
Not Optionable
Beta
2.03

Key Executives

  • Ted WhiteTed White
    President, Chief Executive Officer & Director
  • Terence Kohler
    Chief Financial Officer
  • Gary Goldenberg
    Chief Medical Officer
  • Eugene Scavola
    Executive Vice President-Technical Operations
  • Christopher G. HayesChristopher G. Hayes
    Secretary, Chief Legal & Compliance Officer













VRCA Stock - Frequently Asked Questions

Should I buy or sell Verrica Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VRCA shares.
View VRCA analyst ratings
or view top-rated stocks.

What is Verrica Pharmaceuticals' stock price forecast for 2023?

4 Wall Street analysts have issued 1 year target prices for Verrica Pharmaceuticals' shares. Their VRCA share price forecasts range from $10.00 to $11.00. On average, they anticipate the company's share price to reach $10.67 in the next twelve months. This suggests a possible upside of 64.1% from the stock's current price.
View analysts price targets for VRCA
or view top-rated stocks among Wall Street analysts.

How have VRCA shares performed in 2023?

Verrica Pharmaceuticals' stock was trading at $2.75 at the start of the year. Since then, VRCA stock has increased by 136.4% and is now trading at $6.50.
View the best growth stocks for 2023 here
.

Are investors shorting Verrica Pharmaceuticals?

Verrica Pharmaceuticals saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 301,600 shares, an increase of 24.8% from the February 28th total of 241,600 shares. Based on an average trading volume of 180,200 shares, the short-interest ratio is currently 1.7 days. Approximately 1.2% of the company's shares are short sold.
View Verrica Pharmaceuticals' Short Interest
.

When is Verrica Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our VRCA earnings forecast
.

How were Verrica Pharmaceuticals' earnings last quarter?

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) posted its quarterly earnings data on Monday, March, 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.05. The company had revenue of $0.07 million for the quarter. Verrica Pharmaceuticals had a negative net margin of 271.11% and a negative trailing twelve-month return on equity of 70.83%.

What other stocks do shareholders of Verrica Pharmaceuticals own?
When did Verrica Pharmaceuticals IPO?

(VRCA) raised $75 million in an initial public offering on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen served as the underwriters for the IPO.

What is Verrica Pharmaceuticals' stock symbol?

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

Who are Verrica Pharmaceuticals' major shareholders?

Verrica Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BML Capital Management LLC (2.70%), Millennium Management LLC (0.50%), Geode Capital Management LLC (0.40%), Renaissance Technologies LLC (0.38%), Conning Inc. (0.31%) and Fosun International Ltd (0.31%). Insiders that own company stock include A Brian Davis, Christopher G Hayes, Craig Ballaron, John A Stalfort III, Paul B Manning, Paul B Manning, Perceptive Advisors Llc and Ted White.
View institutional ownership trends
.

How do I buy shares of Verrica Pharmaceuticals?

Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verrica Pharmaceuticals' stock price today?

One share of VRCA stock can currently be purchased for approximately $6.50.

How much money does Verrica Pharmaceuticals make?

Verrica Pharmaceuticals (NASDAQ:VRCA) has a market capitalization of $272.03 million and generates $9.03 million in revenue each year. The company earns $-24,490,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

How can I contact Verrica Pharmaceuticals?

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The official website for the company is www.verrica.com. The company can be reached via phone at (434) 453-3300 or via email at info@verrica.com.

This page (NASDAQ:VRCA) was last updated on 3/31/2023 by MarketBeat.com Staff